The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hepatitis B Vaccine (Recombinant) Market Research Report 2024
Synopsis
Hepatitis B vaccine is a vaccine that prevents hepatitis B.
The global Hepatitis B Vaccine (Recombinant) market was valued at US$ 1021.8 million in 2023 and is anticipated to reach US$ 1271 million by 2030, witnessing a CAGR of 3.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hepatitis B Vaccine (Recombinant), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis B Vaccine (Recombinant).
Report Scope
The Hepatitis B Vaccine (Recombinant) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hepatitis B Vaccine (Recombinant) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hepatitis B Vaccine (Recombinant) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Merck
Sanofi Pasteur
Dynavax Technologies
LG Life Sciences
KM Biologics
Shenzhen Kangtai Biological Products
Serum Institute
Segment by Type
10mcg/0.5ml
10mcg/ml
Segment by Application
Newborn
Adult
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hepatitis B Vaccine (Recombinant) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hepatitis B Vaccine (Recombinant) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Hepatitis B vaccine is a vaccine that prevents hepatitis B.
The global Hepatitis B Vaccine (Recombinant) market was valued at US$ 1021.8 million in 2023 and is anticipated to reach US$ 1271 million by 2030, witnessing a CAGR of 3.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hepatitis B Vaccine (Recombinant), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis B Vaccine (Recombinant).
Report Scope
The Hepatitis B Vaccine (Recombinant) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hepatitis B Vaccine (Recombinant) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hepatitis B Vaccine (Recombinant) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Merck
Sanofi Pasteur
Dynavax Technologies
LG Life Sciences
KM Biologics
Shenzhen Kangtai Biological Products
Serum Institute
Segment by Type
10mcg/0.5ml
10mcg/ml
Segment by Application
Newborn
Adult
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hepatitis B Vaccine (Recombinant) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hepatitis B Vaccine (Recombinant) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Hepatitis B Vaccine (Recombinant) Market Overview
1.1 Product Overview and Scope of Hepatitis B Vaccine (Recombinant)
1.2 Hepatitis B Vaccine (Recombinant) Segment by Type
1.2.1 Global Hepatitis B Vaccine (Recombinant) Market Value Comparison by Type (2024-2030)
1.2.2 10mcg/0.5ml
1.2.3 10mcg/ml
1.3 Hepatitis B Vaccine (Recombinant) Segment by Application
1.3.1 Global Hepatitis B Vaccine (Recombinant) Market Value by Application: (2024-2030)
1.3.2 Newborn
1.3.3 Adult
1.4 Global Hepatitis B Vaccine (Recombinant) Market Size Estimates and Forecasts
1.4.1 Global Hepatitis B Vaccine (Recombinant) Revenue 2019-2030
1.4.2 Global Hepatitis B Vaccine (Recombinant) Sales 2019-2030
1.4.3 Global Hepatitis B Vaccine (Recombinant) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Hepatitis B Vaccine (Recombinant) Market Competition by Manufacturers
2.1 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Hepatitis B Vaccine (Recombinant) Average Price by Manufacturers (2019-2024)
2.4 Global Hepatitis B Vaccine (Recombinant) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Hepatitis B Vaccine (Recombinant), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hepatitis B Vaccine (Recombinant), Product Type & Application
2.7 Hepatitis B Vaccine (Recombinant) Market Competitive Situation and Trends
2.7.1 Hepatitis B Vaccine (Recombinant) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Hepatitis B Vaccine (Recombinant) Players Market Share by Revenue
2.7.3 Global Hepatitis B Vaccine (Recombinant) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hepatitis B Vaccine (Recombinant) Retrospective Market Scenario by Region
3.1 Global Hepatitis B Vaccine (Recombinant) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Hepatitis B Vaccine (Recombinant) Global Hepatitis B Vaccine (Recombinant) Sales by Region: 2019-2030
3.2.1 Global Hepatitis B Vaccine (Recombinant) Sales by Region: 2019-2024
3.2.2 Global Hepatitis B Vaccine (Recombinant) Sales by Region: 2025-2030
3.3 Global Hepatitis B Vaccine (Recombinant) Global Hepatitis B Vaccine (Recombinant) Revenue by Region: 2019-2030
3.3.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Region: 2019-2024
3.3.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Region: 2025-2030
3.4 North America Hepatitis B Vaccine (Recombinant) Market Facts & Figures by Country
3.4.1 North America Hepatitis B Vaccine (Recombinant) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Hepatitis B Vaccine (Recombinant) Sales by Country (2019-2030)
3.4.3 North America Hepatitis B Vaccine (Recombinant) Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Hepatitis B Vaccine (Recombinant) Market Facts & Figures by Country
3.5.1 Europe Hepatitis B Vaccine (Recombinant) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2019-2030)
3.5.3 Europe Hepatitis B Vaccine (Recombinant) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hepatitis B Vaccine (Recombinant) Market Facts & Figures by Country
3.6.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Country (2019-2030)
3.6.3 Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Hepatitis B Vaccine (Recombinant) Market Facts & Figures by Country
3.7.1 Latin America Hepatitis B Vaccine (Recombinant) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Hepatitis B Vaccine (Recombinant) Sales by Country (2019-2030)
3.7.3 Latin America Hepatitis B Vaccine (Recombinant) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Facts & Figures by Country
3.8.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Hepatitis B Vaccine (Recombinant) Sales by Type (2019-2030)
4.1.1 Global Hepatitis B Vaccine (Recombinant) Sales by Type (2019-2024)
4.1.2 Global Hepatitis B Vaccine (Recombinant) Sales by Type (2025-2030)
4.1.3 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type (2019-2030)
4.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Type (2019-2030)
4.2.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Type (2019-2024)
4.2.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Type (2025-2030)
4.2.3 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Type (2019-2030)
4.3 Global Hepatitis B Vaccine (Recombinant) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Hepatitis B Vaccine (Recombinant) Sales by Application (2019-2030)
5.1.1 Global Hepatitis B Vaccine (Recombinant) Sales by Application (2019-2024)
5.1.2 Global Hepatitis B Vaccine (Recombinant) Sales by Application (2025-2030)
5.1.3 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application (2019-2030)
5.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Application (2019-2030)
5.2.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Application (2019-2024)
5.2.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Application (2025-2030)
5.2.3 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Application (2019-2030)
5.3 Global Hepatitis B Vaccine (Recombinant) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Corporation Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GSK Hepatitis B Vaccine (Recombinant) Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Hepatitis B Vaccine (Recombinant) Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Sanofi Pasteur
6.3.1 Sanofi Pasteur Corporation Information
6.3.2 Sanofi Pasteur Description and Business Overview
6.3.3 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Product Portfolio
6.3.5 Sanofi Pasteur Recent Developments/Updates
6.4 Dynavax Technologies
6.4.1 Dynavax Technologies Corporation Information
6.4.2 Dynavax Technologies Description and Business Overview
6.4.3 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Product Portfolio
6.4.5 Dynavax Technologies Recent Developments/Updates
6.5 LG Life Sciences
6.5.1 LG Life Sciences Corporation Information
6.5.2 LG Life Sciences Description and Business Overview
6.5.3 LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 LG Life Sciences Hepatitis B Vaccine (Recombinant) Product Portfolio
6.5.5 LG Life Sciences Recent Developments/Updates
6.6 KM Biologics
6.6.1 KM Biologics Corporation Information
6.6.2 KM Biologics Description and Business Overview
6.6.3 KM Biologics Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 KM Biologics Hepatitis B Vaccine (Recombinant) Product Portfolio
6.6.5 KM Biologics Recent Developments/Updates
6.7 Shenzhen Kangtai Biological Products
6.6.1 Shenzhen Kangtai Biological Products Corporation Information
6.6.2 Shenzhen Kangtai Biological Products Description and Business Overview
6.6.3 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Product Portfolio
6.7.5 Shenzhen Kangtai Biological Products Recent Developments/Updates
6.8 Serum Institute
6.8.1 Serum Institute Corporation Information
6.8.2 Serum Institute Description and Business Overview
6.8.3 Serum Institute Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Serum Institute Hepatitis B Vaccine (Recombinant) Product Portfolio
6.8.5 Serum Institute Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hepatitis B Vaccine (Recombinant) Industry Chain Analysis
7.2 Hepatitis B Vaccine (Recombinant) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hepatitis B Vaccine (Recombinant) Production Mode & Process
7.4 Hepatitis B Vaccine (Recombinant) Sales and Marketing
7.4.1 Hepatitis B Vaccine (Recombinant) Sales Channels
7.4.2 Hepatitis B Vaccine (Recombinant) Distributors
7.5 Hepatitis B Vaccine (Recombinant) Customers
8 Hepatitis B Vaccine (Recombinant) Market Dynamics
8.1 Hepatitis B Vaccine (Recombinant) Industry Trends
8.2 Hepatitis B Vaccine (Recombinant) Market Drivers
8.3 Hepatitis B Vaccine (Recombinant) Market Challenges
8.4 Hepatitis B Vaccine (Recombinant) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Hepatitis B Vaccine (Recombinant) Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Hepatitis B Vaccine (Recombinant) Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Hepatitis B Vaccine (Recombinant) Market Competitive Situation by Manufacturers in 2023
Table 4. Global Hepatitis B Vaccine (Recombinant) Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Hepatitis B Vaccine (Recombinant) Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Hepatitis B Vaccine (Recombinant) Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Hepatitis B Vaccine (Recombinant) Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Hepatitis B Vaccine (Recombinant), Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Hepatitis B Vaccine (Recombinant), Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Hepatitis B Vaccine (Recombinant), Product Type & Application
Table 12. Global Key Manufacturers of Hepatitis B Vaccine (Recombinant), Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Hepatitis B Vaccine (Recombinant) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatitis B Vaccine (Recombinant) as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Hepatitis B Vaccine (Recombinant) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Hepatitis B Vaccine (Recombinant) Sales by Region (2019-2024) & (K Units)
Table 18. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Region (2019-2024)
Table 19. Global Hepatitis B Vaccine (Recombinant) Sales by Region (2025-2030) & (K Units)
Table 20. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Region (2025-2030)
Table 21. Global Hepatitis B Vaccine (Recombinant) Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Region (2019-2024)
Table 23. Global Hepatitis B Vaccine (Recombinant) Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Region (2025-2030)
Table 25. North America Hepatitis B Vaccine (Recombinant) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Hepatitis B Vaccine (Recombinant) Sales by Country (2019-2024) & (K Units)
Table 27. North America Hepatitis B Vaccine (Recombinant) Sales by Country (2025-2030) & (K Units)
Table 28. North America Hepatitis B Vaccine (Recombinant) Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Hepatitis B Vaccine (Recombinant) Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Hepatitis B Vaccine (Recombinant) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2019-2024) & (K Units)
Table 32. Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2025-2030) & (K Units)
Table 33. Europe Hepatitis B Vaccine (Recombinant) Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Hepatitis B Vaccine (Recombinant) Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Hepatitis B Vaccine (Recombinant) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Hepatitis B Vaccine (Recombinant) Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Hepatitis B Vaccine (Recombinant) Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Hepatitis B Vaccine (Recombinant) Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Hepatitis B Vaccine (Recombinant) Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Hepatitis B Vaccine (Recombinant) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Hepatitis B Vaccine (Recombinant) Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Hepatitis B Vaccine (Recombinant) Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Hepatitis B Vaccine (Recombinant) Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Hepatitis B Vaccine (Recombinant) Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Hepatitis B Vaccine (Recombinant) Sales (K Units) by Type (2019-2024)
Table 51. Global Hepatitis B Vaccine (Recombinant) Sales (K Units) by Type (2025-2030)
Table 52. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type (2019-2024)
Table 53. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type (2025-2030)
Table 54. Global Hepatitis B Vaccine (Recombinant) Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Hepatitis B Vaccine (Recombinant) Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Type (2019-2024)
Table 57. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Type (2025-2030)
Table 58. Global Hepatitis B Vaccine (Recombinant) Price (US$/Unit) by Type (2019-2024)
Table 59. Global Hepatitis B Vaccine (Recombinant) Price (US$/Unit) by Type (2025-2030)
Table 60. Global Hepatitis B Vaccine (Recombinant) Sales (K Units) by Application (2019-2024)
Table 61. Global Hepatitis B Vaccine (Recombinant) Sales (K Units) by Application (2025-2030)
Table 62. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application (2019-2024)
Table 63. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application (2025-2030)
Table 64. Global Hepatitis B Vaccine (Recombinant) Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Hepatitis B Vaccine (Recombinant) Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Application (2019-2024)
Table 67. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Application (2025-2030)
Table 68. Global Hepatitis B Vaccine (Recombinant) Price (US$/Unit) by Application (2019-2024)
Table 69. Global Hepatitis B Vaccine (Recombinant) Price (US$/Unit) by Application (2025-2030)
Table 70. GSK Corporation Information
Table 71. GSK Description and Business Overview
Table 72. GSK Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. GSK Hepatitis B Vaccine (Recombinant) Product
Table 74. GSK Recent Developments/Updates
Table 75. Merck Corporation Information
Table 76. Merck Description and Business Overview
Table 77. Merck Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Merck Hepatitis B Vaccine (Recombinant) Product
Table 79. Merck Recent Developments/Updates
Table 80. Sanofi Pasteur Corporation Information
Table 81. Sanofi Pasteur Description and Business Overview
Table 82. Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Product
Table 84. Sanofi Pasteur Recent Developments/Updates
Table 85. Dynavax Technologies Corporation Information
Table 86. Dynavax Technologies Description and Business Overview
Table 87. Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Dynavax Technologies Hepatitis B Vaccine (Recombinant) Product
Table 89. Dynavax Technologies Recent Developments/Updates
Table 90. LG Life Sciences Corporation Information
Table 91. LG Life Sciences Description and Business Overview
Table 92. LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. LG Life Sciences Hepatitis B Vaccine (Recombinant) Product
Table 94. LG Life Sciences Recent Developments/Updates
Table 95. KM Biologics Corporation Information
Table 96. KM Biologics Description and Business Overview
Table 97. KM Biologics Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. KM Biologics Hepatitis B Vaccine (Recombinant) Product
Table 99. KM Biologics Recent Developments/Updates
Table 100. Shenzhen Kangtai Biological Products Corporation Information
Table 101. Shenzhen Kangtai Biological Products Description and Business Overview
Table 102. Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Product
Table 104. Shenzhen Kangtai Biological Products Recent Developments/Updates
Table 105. Serum Institute Corporation Information
Table 106. Serum Institute Description and Business Overview
Table 107. Serum Institute Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Serum Institute Hepatitis B Vaccine (Recombinant) Product
Table 109. Serum Institute Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Hepatitis B Vaccine (Recombinant) Distributors List
Table 113. Hepatitis B Vaccine (Recombinant) Customers List
Table 114. Hepatitis B Vaccine (Recombinant) Market Trends
Table 115. Hepatitis B Vaccine (Recombinant) Market Drivers
Table 116. Hepatitis B Vaccine (Recombinant) Market Challenges
Table 117. Hepatitis B Vaccine (Recombinant) Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Hepatitis B Vaccine (Recombinant)
Figure 2. Global Hepatitis B Vaccine (Recombinant) Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Hepatitis B Vaccine (Recombinant) Market Share by Type in 2023 & 2030
Figure 4. 10mcg/0.5ml Product Picture
Figure 5. 10mcg/ml Product Picture
Figure 6. Global Hepatitis B Vaccine (Recombinant) Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Hepatitis B Vaccine (Recombinant) Market Share by Application in 2023 & 2030
Figure 8. Newborn
Figure 9. Adult
Figure 10. Global Hepatitis B Vaccine (Recombinant) Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Hepatitis B Vaccine (Recombinant) Market Size (2019-2030) & (US$ Million)
Figure 12. Global Hepatitis B Vaccine (Recombinant) Sales (2019-2030) & (K Units)
Figure 13. Global Hepatitis B Vaccine (Recombinant) Average Price (US$/Unit) & (2019-2030)
Figure 14. Hepatitis B Vaccine (Recombinant) Report Years Considered
Figure 15. Hepatitis B Vaccine (Recombinant) Sales Share by Manufacturers in 2023
Figure 16. Global Hepatitis B Vaccine (Recombinant) Revenue Share by Manufacturers in 2023
Figure 17. The Global 5 and 10 Largest Hepatitis B Vaccine (Recombinant) Players: Market Share by Revenue in 2023
Figure 18. Hepatitis B Vaccine (Recombinant) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 19. Global Hepatitis B Vaccine (Recombinant) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2019-2030)
Figure 21. North America Hepatitis B Vaccine (Recombinant) Revenue Market Share by Country (2019-2030)
Figure 22. U.S. Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2019-2030)
Figure 25. Europe Hepatitis B Vaccine (Recombinant) Revenue Market Share by Country (2019-2030)
Figure 26. Germany Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Russia Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Hepatitis B Vaccine (Recombinant) Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue Market Share by Region (2019-2030)
Figure 33. China Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Australia Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Taiwan Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Indonesia Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Thailand Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Malaysia Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Philippines Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2019-2030)
Figure 44. Latin America Hepatitis B Vaccine (Recombinant) Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Hepatitis B Vaccine (Recombinant) Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. UAE Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Hepatitis B Vaccine (Recombinant) by Type (2019-2030)
Figure 54. Global Revenue Market Share of Hepatitis B Vaccine (Recombinant) by Type (2019-2030)
Figure 55. Global Hepatitis B Vaccine (Recombinant) Price (US$/Unit) by Type (2019-2030)
Figure 56. Global Sales Market Share of Hepatitis B Vaccine (Recombinant) by Application (2019-2030)
Figure 57. Global Revenue Market Share of Hepatitis B Vaccine (Recombinant) by Application (2019-2030)
Figure 58. Global Hepatitis B Vaccine (Recombinant) Price (US$/Unit) by Application (2019-2030)
Figure 59. Hepatitis B Vaccine (Recombinant) Value Chain
Figure 60. Hepatitis B Vaccine (Recombinant) Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
